Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026)
Apogee Therapeutics' (APGE) quarterly Return on Capital Employed came in at 28.2% in Q1 2026, up 628.0% year-on-year from 3.87% in Q1 2025, and up 25.57% on a QoQ basis from 37.89% in Q4 2025.
Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 4 years of Return on Capital Employed data on file, last reported at 28.2% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 628.0% year-over-year to 28.2% in Q1 2026; TTM through Mar 2026 was 28.2%, a 628.0% increase from a year earlier, with the FY2025 full-year figure at 34.93%, up 456.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.2%, up from 37.89% in the prior quarter.
- Over the last five years, Return on Capital Employed for APGE reached as high as 18.25% in Q2 2024 and fell as low as 46.62% in Q3 2025.
- Historically, Return on Capital Employed has averaged 30.03% across 4 years, with a median of 28.2% in 2026.
- Across the five-year window, Return on Capital Employed plunged 2313 bps in 2025 and soared 628 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 23.64% in 2023, then declined by 25 bps to 29.44% in 2024, then dropped by 29 bps to 37.89% in 2025, then gained by 26 bps to 28.2% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 28.2% in Q1 2026, 37.89% in Q4 2025, and 46.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Apogee Therapeutics | 9.35 Bn | 8.29 Bn | - | -28.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.20% |
| Dec 31, 2025 | -37.89% |
| Sep 30, 2025 | -46.62% |
| Jun 30, 2025 | -41.38% |
| Mar 31, 2025 | -34.49% |
| Dec 31, 2024 | -29.44% |
| Sep 30, 2024 | -23.57% |
| Jun 30, 2024 | -18.25% |
| Mar 31, 2024 | -20.06% |
| Dec 31, 2023 | -23.64% |
| Sep 30, 2023 | -26.76% |